New drug HS-20152 gets first human safety check
NCT ID NCT07503015
First seen Apr 05, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This early-stage study will test the safety and tolerability of a single dose of HS-20152, a new drug that targets the complement pathway (part of the immune system), in 32 healthy adults aged 18 to 64. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. The goal is to gather initial safety data before testing the drug in people with specific diseases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.